ArticleBMC medical imaging2026
Exploring the key clinical and computed tomography features for distinguishing high-grade lung cancers from morphologically similar benign tumors: a two-center case-control study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSome high-grade lung cancers (HGLCs) and pulmonary benign tumors (PBTs) exhibit similar computed tomography (CT) features. This study aims to determine the key clinical and CT features for identifying HGLCs.
methodsFrom 2011 to 2025, 102 HGLCs presenting as regular solid nodules (SNs) and 102 size-matched PBTs were retrospectively enrolled. Clinical data and qualitative and quantitative CT indicators of lesions were analyzed and compared. Firth’s penalized logistic regression was used to identify independent predictors, and model performance was evaluated using 5-fold cross-validation.
resultsCompared to patients with PBTs, those with HGLCs were more likely to be male, older, and symptomatic individuals and smokers, with greater smoking amount (all P < 0.05). HGLCs also demonstrated higher rates of mediastinal/hilar lymph node enlargement, vascular encasement, and bronchial obstruction, while calcification was absent (all P < 0.001). The male (odds ratio [OR], 42.340; 95% confidence interval [CI], 2.283 -785.149; P = 0.012), high pack-years (> 27.6) (OR, 1.161; 95%CI, 1.022–1.321; P = 0.022), mediastinal/hilar lymph node enlargement (OR, 208.631; 95% CI, 6.477–6720.607; P = 0.003), bronchial obstruction (OR, 34.375; 95% CI, 2.314–196.064; P = 0.010), and vascular encasement (OR, 39.650; 95% CI, 9.089–67.752; P = 0.002) were revealed as independent predictors of HGLCs.
conclusionsIn male heavy smokers, SNs with morphological features of PBTs but exhibiting vascular encasement, bronchial obstruction, or mediastinal/hilar lymph node enlargement warrant closer monitoring or further evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.